Edward A. Bortnichak, PhD

Pharmacoepidemiology, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., West Point, Pennsylvania

JCP
Original Research

November 30, 2021

This study used 2 insurance databases to estimate the prevalence of treatment-resistant depression among US patients with pharmaceutically treated depression.
Xinyue Liu, Yuki Mukai, Christine I. Furtek, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe